DUBLIN--(BUSINESS WIRE)--The "Cancer Immunotherapy Market: Global Industry Analysis, Trends, Market Size and Forecasts up to 2024" report has been added to ResearchAndMarkets.com's offering.
The report predicts the global cancer immunotherapy market to grow with a CAGR of 14.5% over the period of 2018 - 2024.
The report on cancer immunotherapy market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global cancer immunotherapy market over the period of 2016 to 2024. Moreover, the report is collective presentation of primary and secondary research findings.
Porter's Five Forces model in the report provides insights into the competitive rivalry, supplier and buyer positions in the market and opportunities for the new entrants in the global cancer immunotherapy market over the period of 2016 - 2024. Further, the author's Growth Matrix given in the report brings an insight on the investment areas that existing or new market players can consider.
The global cancer immunotherapy market is segmented on the basis of therapeutic area, end users, and therapy type.
Global Cancer Immunotherapy Market by Therapeutic Area
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Blood Cancer
- Prostate Cancer
Global Cancer Immunotherapy Market by End Users
- Asc's (Ambulatory Surgical Centers)
- Cancer Research Centers
Global Cancer Immunotherapy Market by Therapy Type
- Monoclonal Antibodies
- Immune System Modulators
- Immune Checkpoint Inhibitors
- Cancer Vaccines
Global Cancer Immunotherapy Market by Regions
- North America
- Glaxosmithkline Plc
- F.Hoffmann-La Roche Ltd.
- Eli Lilly and Company
- Pfizer, Inc.
- Bristol-Myers Squibb Company
- AstraZenca Plc
- Amgen, Inc.
- Novartis AG
Merck & Co., Inc.
For more information about this report visit https://www.researchandmarkets.com/research/lnmbpj/cancer?w=4